Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Eris Lifesciences Ltd (ERIS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540596 NSE: ERIS Pharmaceuticals & Drugs | Small Cap | Eris Lifesciences Share Price
₹1,353.50 -1.15 (-0.08%)
As on 11-Sep'26 15:13
Eris Lifesciences Ltd (ERIS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540596 NSE: ERIS Pharmaceuticals & Drugs | Small Cap | Eris Lifesciences Share Price
₹1,353.50 -1.15 (-0.08%)
As on 11-Sep'26 15:13
Key Metrics
Valuation Multiples
Market Cap
₹18,773 Cr.
Current Price
₹1,353.5
52-Week Low / High
₹1,238 / 1,737
TTM EPS
₹46.5
TTM Sales
₹3,212 Cr.
Book Value per Share
₹291
P/E Ratio
29.16
Lower than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
4.66
Lower than its 5-year historical median
Price to Sales (P/S)
5.84
Lower than its 5-year historical median
EV/EBITDA
18.32
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
19.23%
Outperforms industry median
Return on Capital Employed (ROCE)
14.47%
Outperforms industry median
Return on Assets (ROA)
9.18%
Operating Profit Margin
35.5%
Net Profit Margin
20.69%
Gross Profit Margin
28.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
7.3%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
9.07%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
72.82%
Asset Quality
Promoter Holding
54.14%
Pledged shares (%) of Promoter's holding (%)
16.85%
Reserves
₹4,018 Cr.
Equity
₹13.9 Cr.
Face Value
₹1
All Time Low / High
₹341.05 / 1909.55
Check Before You Invest
Quality
Very GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Eris Lifesciences Ltd a good quality company?
Eris Lifesciences Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Eris Lifesciences Ltd performance compare with that of its Peers?
Revenue growth of Eris Lifesciences Ltd vs industry peers?
Eris Lifesciences Ltd revenue CAGR is 20.89%, compared to the industry median CAGR of 5.76%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Eris Lifesciences Ltd?
Promoters hold 54.14% of the Eris Lifesciences Ltd, with 16.85% of their stake pledged, indicating high pledge risk.
Stock return of Eris Lifesciences Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 11.61% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Eris Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 62.4% | 35.5% | 26% | 24.7% | 27.1% | 26.4% | 20.5% | 10.2% | 7% | 10.8% | - |
| Value Creation Index ⓘ | 3.5 | 1.6 | 0.9 | 0.8 | 1.0 | 1.0 | 0.5 | -0.3 | -0.5 | -0.2 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 713 | 761 | 897 | 1,020 | 1,109 | 1,216 | 1,331 | 1,487 | 1,698 | 1,822 | 1,646 |
| Sales YoY Gr. | - | 6.7% | 17.9% | 13.8% | 8.7% | 9.6% | 9.5% | 11.7% | 14.2% | 7.3% | - |
| Adj EPS ⓘ | 16.9 | 20.1 | 19.4 | 21.2 | 25.7 | 30.8 | 28.9 | 21.9 | 5.6 | 18.3 | 13.9 |
| YoY Gr. | - | 19.1% | -3.9% | 9.6% | 21.1% | 19.9% | -6% | -24.5% | -74.5% | 228.3% | - |
| BVPS (₹) ⓘ | 41.8 | 63.1 | 84 | 95.5 | 115.7 | 141 | 163.2 | 185.2 | 183.9 | 229.7 | 233.1 |
| Adj Net Profit ⓘ | 232 | 277 | 266 | 288 | 349 | 419 | 394 | 297 | 75.9 | 254 | 192 |
| Cash Flow from Ops. ⓘ | 210 | 236 | 216 | 265 | 395 | 369 | 322 | 336 | 702 | 564 | - |
| Debt/CF from Ops. ⓘ | 0 | 1.6 | 0.8 | 0 | 0 | 0 | 1 | 7.5 | 3.2 | 3.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 11% | 10.4% | 11% | 7.3% | ||||
| Adj EPS ⓘ | 0.9% | -6.5% | -14.1% | 228.3% | ||||
| BVPSⓘ | 20.9% | 14.7% | 12.1% | 24.9% | ||||
| Share Price | - | 12% | 18.4% | -20.1% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 52.8 | 38.4 | 26.3 | 23.5 | 24.3 | 24 | 19 | 12.5 | 3 | 8.9 | 6 |
| Op. Profit Mgn % ⓘ | 38.3 | 41.5 | 37.3 | 35.2 | 37.7 | 40.2 | 38 | 30.7 | 28.7 | 32.9 | 31.4 |
| Net Profit Mgn % ⓘ | 32.6 | 36.4 | 29.7 | 28.2 | 31.4 | 34.4 | 29.6 | 20 | 4.5 | 13.9 | 11.7 |
| Debt to Equity ⓘ | 0 | 0.4 | 0.2 | 0 | 0 | 0 | 0.1 | 1 | 0.9 | 0.7 | - |
| Working Cap Days ⓘ | 79 | 118 | 128 | 127 | 138 | 146 | 156 | 154 | 224 | 322 | 125 |
| Cash Conv. Cycle ⓘ | 11 | -2 | -4 | 7 | 7 | 4 | 22 | 34 | 32 | 16 | -58 |
Valuation of Eris Lifesciences - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 18.51 | 18.51 | 18.51 | 18.51 | 18.51 | 16.93 | 16.92 | 16.92 | 16.92 | 16.85 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 749 | 856 | 982 | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 |
| Operating Expenses ⓘ + | 480 | 533 | 637 | 706 | 781 | 862 | 1,148 | 1,334 | 1,876 | 2,020 |
| Operating Profit ⓘ | 269 | 322 | 345 | 368 | 431 | 485 | 537 | 675 | 1,017 | 1,109 |
| Operating Profit Margin (%) | 35.9% | 37.6% | 35.1% | 34.3% | 35.5% | 36.0% | 31.9% | 33.6% | 35.2% | 35.5% |
| Other Income ⓘ + | 25 | 26 | 32 | 16 | 9 | 26 | 11 | 24 | 18 | 18 |
| Interest ⓘ | 1 | 11 | 23 | 2 | 2 | 4 | 26 | 85 | 231 | 193 |
| Depreciation ⓘ | 23 | 26 | 36 | 50 | 43 | 65 | 117 | 183 | 315 | 280 |
| Profit Before Tax ⓘ | 270 | 312 | 317 | 331 | 394 | 442 | 405 | 431 | 489 | 639 |
| Tax ⓘ | 24 | 17 | 26 | 35 | 39 | 36 | 30 | 34 | 114 | -9 |
| Profit After Tax | 247 | 295 | 291 | 297 | 355 | 406 | 374 | 397 | 375 | 648 |
| PAT Margin (%) | 32.9% | 34.5% | 29.6% | 27.6% | 29.3% | 30.1% | 22.2% | 19.8% | 13.0% | 20.7% |
| Adjusted EPS (₹) | 18.0 | 21.4 | 21.2 | 21.8 | 26.2 | 29.9 | 28.1 | 28.8 | 25.8 | 44.7 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 13.10% | 21% | 20.10% | 26.20% | 0% | 28.50% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 567 | 861 | 1,149 | 1,293 | 1,572 | 1,906 | 2,193 | 2,581 | 2,844 | 3,888 | |
| Debt + | 0 | 274 | 0 | 0 | 0 | 45 | 699 | 1,966 | 2,134 | 1,410 | |
| Minority Interest | 24 | 25 | 18 | 0 | 0 | -0 | 25 | 636 | 417 | -7 | |
| Trade Payables | 39 | 91 | 84 | 100 | 103 | 118 | 125 | 219 | 332 | 330 | |
| Others Liabilities ⓘ | 102 | 177 | 229 | 43 | 28 | 44 | 430 | 1,409 | 1,137 | 1,626 | |
| Total Liabilities ⓘ | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,472 | 6,810 | 6,866 | 7,247 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 232 | 771 | 761 | 875 | 854 | 918 | 2,568 | 4,319 | 5,306 | 5,188 | |
| CWIP ⓘ | 0 | 0 | 3 | 4 | 2 | 27 | 22 | 20 | 67 | 171 | |
| Investments ⓘ | 303 | 365 | 356 | 78 | 294 | 520 | 37 | 16 | 67 | 62 | |
| Inventories | 56 | 65 | 83 | 69 | 94 | 118 | 131 | 189 | 335 | 437 | |
| Trade Receivables | 49 | 67 | 84 | 157 | 140 | 161 | 293 | 422 | 459 | 680 | |
| Cash Equivalents | 2 | 11 | 8 | 67 | 38 | 52 | 58 | 1,401 | 223 | 67 | |
| Others Assets ⓘ | 90 | 149 | 187 | 186 | 280 | 316 | 363 | 444 | 409 | 642 | |
| Total Assets ⓘ | 732 | 1,428 | 1,481 | 1,437 | 1,703 | 2,113 | 3,472 | 6,810 | 6,866 | 7,247 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 200 | 235 | 223 | 271 | 375 | 378 | 292 | 486 | 1,065 | 538 |
| Cash Flow From Investing Activity ⓘ + | -184 | -590 | -5 | 123 | -323 | -320 | -982 | -1,855 | -80 | -369 |
| Cash Flow From Financing Activity ⓘ + | -24 | 363 | -221 | -335 | -82 | -45 | 688 | 1,380 | -881 | -314 |
| Net Cash Flow ⓘ | -8 | 8 | -3 | 60 | -30 | 14 | -2 | 11 | 104 | -145 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 56.9 | 41.3 | 28.96 | 24.28 | 24.78 | 23.33 | 18.25 | 16.64 | 13.81 | 19.23 |
| ROCE (%) | 62.56 | 35.76 | 26.54 | 25.44 | 27.6 | 25.29 | 17.3 | 12.37 | 13.59 | 14.47 |
| Asset Turnover Ratio | 1.33 | 0.79 | 0.68 | 0.74 | 0.79 | 0.73 | 0.63 | 0.41 | 0.43 | 0.46 |
| PAT to CFO Conversion(x) | 0.81 | 0.8 | 0.77 | 0.91 | 1.06 | 0.93 | 0.78 | 1.22 | 2.84 | 0.83 |
| Working Capital Days | ||||||||||
| Receivable Days | 18.10 | 24.60 | 28 | 40.90 | 43.60 | 39.40 | 46.90 | 61.70 | 54.10 | 63.90 |
| Inventory Days | 25.20 | 25.90 | 27.50 | 25.90 | 24 | 27.80 | 25.80 | 27.70 | 32.20 | 43.30 |
| Payable Days | 86.20 | 166.70 | 207.70 | 196 | 155.20 | 155.60 | 125.60 | 165 | 140.90 | 151.90 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Eris Lifesciences Ltd FAQs
The current trading price of Eris Lifesciences on 11-Sep-2026 15:13 is ₹1,353.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 10-Sep-2026 the market cap of Eris Lifesciences stood at ₹18,773.2 Cr
The latest P/E ratio of Eris Lifesciences as of 10-Sep-2026 is 97.59.
The latest P/B ratio of Eris Lifesciences as of 10-Sep-2026 is 5.81.
The 52-week high of Eris Lifesciences is ₹1,737 and the 52-week low is ₹1,237.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Eris Lifesciences is ₹1,646 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Eris Lifesciences Ltd is a good quality company.
The key valuation ratios of Eris Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Eris Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Eris Lifesciences Ltd
Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.
The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.
The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.
Business area of the company
The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.
History and milestones
- 2007: Incorporation of the company.
- 2007: Launched “Eris” division focused on cardiology and diabetes segment.
- 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
- 2009: Launched “Adura” division focused on cardiology and diabetes segment.
- 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
- 2012: Launched “Inspira” division focused on cardiology segment.
- 2014: Launched “Victus” division focused on anti-diabetes segment.
- 2014: Set up Assam Facility by the company.
- 2015: Launched “Eris 2” division focused on pain management segment.
- 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
- 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
- 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
- 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
- 2017: Eris acquires 40 trademarks from Amay Pharma
- 2017: Eris acquires Pune based UTH Healthcare.
- 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
- 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
- 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.
You have 33 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
